La cadena de opciones muestra datos clave de las opciones de acciones de Alvotech a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Alvotech..

Alvotech (NASDAQ:ALVO) Bolsa, Cadena de Opciones

Alvotech

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BBGI

BCAX

ELTX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TMCI

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

ALVOPETRO ENEGY LTD by Alvopetro Energy Ltd

Alvopetro Energy Ltd

ALVO MINERALS LTD by ALVO MINERALS LTD.

Cigna Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) short percent of float has fallen 11.26% since its last report. The company recently reported that it has 3.67 million shares sold short, which is 1.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.16 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Cigna Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741095057_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cigna Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cigna Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cigna Group's peer group average for short interest as a percentage of float is 9.82%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About Cigna Group?

Revvity's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) short percent of float has risen 15.51% since its last report. The company recently reported that it has 4.48 million shares sold short, which is 4.99% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.72 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Revvity Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741095051_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Revvity has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Revvity's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Revvity's peer group average for short interest as a percentage of float is 5.35%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

RVTY

What Does the Market Think About Revvity?

Agilent Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) short percent of float has fallen 8.53% since its last report. The company recently reported that it has 2.97 million shares sold short, which is 1.18% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.01 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Agilent Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741095045_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Agilent Technologies has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Agilent Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Agilent Technologies's peer group average for short interest as a percentage of float is 5.52%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Do Investors Really Feel About Agilent Technologies?

Managing a company's finances is a complex task, and having one person with exclusive access to a business's primary bank account can pose serious risks. In a <a href="https://www.youtube.com/watch?v=oh-GzyApi00">recent episode</a> of "EntreLeadership," financial expert <a href="https://www.benzinga.com/personal-finance/25/02/44016490/21-year-old-pro-investor-challenges-dave-ramsey-show-hosts-on-index-funds-vs-mutual-funds-80-of-mutual-funds-dont-beat-the-market">Dave Ramsey</a> addressed a concern from Emery, a CFO at a $50 million home services company, who found himself in a difficult situation: the company's long-time controller had sole access to critical financial accounts and was resistant to change.
<h2 class="wp-block-heading">Identifying the Problem</h2>
Emery explained that his company, with 200 employees, had relied on the same controller for 20 years. While he respected her tenure, her unwillingness to transition from cash-based to accrual accounting was becoming a major issue. Additionally, she retained control of bank accounts, account logins, and key business processes, making it difficult for the company to move forward without significant disruption.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>
Ramsey immediately pointed out the dangers of having only one person with access to such crucial financial information. "If she got hit by a car, y'all'd be screwed," he said bluntly. The risk wasn't just about trust—it was about ensuring business continuity.
<h2 class="wp-block-heading">Implementing a Transition Plan</h2>
Ramsey advised that the first step should be to immediately establish redundancy in the company's financial access. He suggested Emery and the CEO schedule an urgent meeting with the controller to change the situation right away.
He advised taking these steps:
<ul>
<li>Gain Immediate Access: Both the CFO and CEO should obtain login credentials, passwords, and signatures for all business accounts within 24 hours.</li>
<li>Document Financial Processes: The controller should outline key processes, including how vendor payments are handled and how incoming cash is applied.</li>
<li>Apologize, but Be Firm: Rather than framing this as a personal attack, leadership should acknowledge that the company's system was flawed from the beginning and now needed fixing.</li>
<li>Separate the Financial Fix from Performance Issues: Ramsey emphasized that the controller's attitude and reluctance to change is a separate issue and resolving the financial access problem had to come first.</li>
</ul>
Trending: <a href="https://www.benzinga.com/money/millionaires-never-earned-six-figures-according-to-dave-ramsey">69% of Millionaires Never Earned A Six-Figure Salary – Here Are 2 Things They Do To Get Their First $1 Million, According To Dave Ramsey</a>
<h2 class="wp-block-heading">Preparing for Future Financial Security</h2>
Beyond solving the immediate issue, Ramsey stressed the importance of never allowing a similar situation to develop again. A business should always have multiple authorized individuals with financial access to prevent bottlenecks, internal power struggles, or <a href="https://www.benzinga.com/personal-finance/25/02/43759664/trump-investigates-u-s-debt-for-fraud-suggests-treasury-payments-might-not-count">potential fraud</a>.
Another key takeaway was the company's need to transition to accrual accounting. Ramsey noted that businesses earning $50 million in revenue are required by the IRS to use accrual accounting for tax purposes. More importantly, accrual accounting provides a clearer picture of a company's financial health, helping with inventory management and strategic planning.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
<h2 class="wp-block-heading">Final Thoughts</h2>
The lesson from this situation is clear: no single person should have sole financial control in a company of any size, let alone one generating $50 million in revenue. By implementing stronger financial controls, documenting key processes, and ensuring multiple team members have access to critical accounts, businesses can avoid unnecessary risks and ensure <a href="https://www.benzinga.com/content/43741261/how-superior-customer-experience-drives-revenue-growth-in-the-financial-sector">smooth financial operations</a>.
For business owners and financial leaders, Ramsey's advice serves as a crucial reminder: always build systems that protect the company—not just the people within it.
Read Next:
<ul>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>

Personal Finance

What To Do When One Person Has Sole Bank Account Access For A $50M Company? Dave Ramsey Weighs In

Wells Fargo analyst Daniel Politzer maintains Choice Hotels Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>) with a Underweight and lowers the price target from $138 to $137.

Price Target

Analyst Ratings

Wells Fargo Maintains Underweight on Choice Hotels Intl, Lowers Price Target to $137

President Donald Trump&#8216;s recent crypto reserve plan has sparked discontent among his tech community supporters. The plan, announced on Sunday, has led to a significant divide among his tech allies.
What Happened:  The crypto enthusiasts have not welcomed President Trump&#8217;s decision to establish a strategic crypto reserve for the U.S., CNBC <a href="https://www.cnbc.com/2025/03/04/pro-trump-techies-enraged-by-crypto-reserve-plan-causing-early-rift.html">reported</a> on Tuesday. The reserve will comprise not only Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) but also other digital currencies such as Ether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Solana&#8217;s SOL token (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), and Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>).
Trump&#8217;s initial moves to cut regulations and form a digital assets working group were applauded. However, this recent move is seen as an overreach. The tech community had anticipated an exclusive strategic Bitcoin reserve, which would involve purchasing Bitcoin with cash, a decentralized currency seen as a viable alternative to hard money.
Tyler Winklevoss, co-founder of crypto exchange Gemini, stated, "I have nothing against XRP, SOL, or ADA but I do not think they are suitable for a Strategic Reserve."&nbsp;Winklevoss had supported Trump during his election campaign.
Explaining the issue with other coins, &nbsp;Alexander Blume, CEO of Two Prime said, "They're not scarce in the same way and they're not decentralized in the same way. So it reduces the value and signal of creating a Bitcoin reserve.&#8221;
The decision to include riskier assets in the reserve has faced criticism. Detractors argue that this could potentially enhance&nbsp;the net worth of a&nbsp;select group of coin owners, using U.S. taxpayer money. This is particularly troubling to those who support Elon Musk&#8216;s mission to decrease government spending at the Department of Government Efficiency (DOGE).
Creator of blockchain startup Civic, Vinny Lingham wrote on X, "Call me old fashioned but I don't think the government should be pumping our crypto bags with taxpayer money while we are running a near $2trn deficit."
SEE ALSO: <a href="https://www.benzinga.com/25/03/44105530/tesla-introduces-0-apr-financing-on-model-3-purchases-to-check-falling-demand">Elon Musk&#8217;s Tesla Introduces 0% APR Financing On Model 3 Purchases Amid Falling Demand</a>
Why It Matters: Previously, analysts at Bernstein <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44077079/analysts-doubt-us-crypto-reserve-expansion-beyond-bitcoin-cite-funding-challenges">expressed doubts </a>about the U.S. expanding its crypto reserve beyond Bitcoin due to funding challenges, as reported. The rationale for including other assets remains unclear.
On the other hand, Strategy&#8217;s Michael Saylor told CNBC that it was no surprise that the reserve included other cryptocurrencies too. "There's no way to interpret this other than this is bullish for Bitcoin and bullish for the entire U.S. crypto industry," stated Saylor.
To add to the concerns, David Bailey, CEO of Bitcoin Magazine, revealed that <a href="https://www.benzinga.com/25/03/44100824/china-working-behind-closed-doors-to-create-strategic-bitcoin-reserve-says-bitcoiner-who-orange-pilled-trump">China was secretly </a>discussing&nbsp;the creation of a strategic&nbsp;Bitcoin reserve. This could potentially put the U.S. at a strategic disadvantage if it does not focus on Bitcoin.
After a weekend rally, crypto prices on Monday witnessed a significant decline. Bitcoin dropped about 9%, while Ether fell 15%. XRP and SOL also witnessed substantial drops. This decline is believed to be linked to President Trump&#8217;s confirmation of upcoming tariffs.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/03/44103610/taiwan-semiconductor-doubles-down-on-us-chipmaking-165-billion-investment-set-to-reshape-tech-jobs">Taiwan Semiconductor Doubles Down On US Chipmaking, Plans $165 Billion Investment</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$BTC

$ETH

$SOL

$XRP

Trump's Crypto Reserve Plan Sparks Backlash From Fans For Adding Ether, XRP, Solana, Cardano: 'Don't Think The Government Should Be Pumping Our Crypto Bags With Taxpayer Money'

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4375346-1&amp;h=205362250&amp;u=https%3A%2F%2Fwww.luciddx.com%2F&amp;a=Lucid+Diagnostics+Inc.">Lucid Diagnostics Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>)&nbsp;("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>), today announced that it has entered into subscription agreements with certain accredited investors to sell 13,939,331 shares of common stock at a purchase price of $1.10 per share in a registered direct offering. The gross proceeds to the Company from this offering are expected to be approximately $15.3 million, before deducting the approximately $0.8 million in placement agent's fees and other offering expenses payable by the Company.
Canaccord Genuity is acting as the sole placement agent for this offering.

Offerings

LUCD

PAVM

Lucid Diagnostics Announces $15.3M Registered Direct Offering Of 13,939,331 Shares Of Common Stock At A Purchase Price Of $1.10 Per Share

Telsey Advisory Group analyst Dana Telsey maintains Olaplex Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) with a Market Perform and maintains $2 price target.

OLPX

Telsey Advisory Group Maintains Market Perform on Olaplex Hldgs, Maintains $2 Price Target

Barrington Research analyst Gary Prestopino maintains Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) with a Outperform and maintains $110 price target.

DAVE

Barrington Research Maintains Outperform on Dave, Maintains $110 Price Target

Shares of Target Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) are trading lower in <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">premarket on Tuesday</a> after the fourth-quarter FY24 earnings.
The company reported a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44103957/target-corporation-reports-fourth-quarter-and-full-year-2024-earnings" rel="noreferrer noopener">fourth-quarter sales decline </a>of 3.1% year-on-year to $30.91 billion, beating the analyst consensus estimate of $30.84 billion.
Comparable sales increased 1.5% in the fourth quarter, reflecting strong traffic and digital performance. Digital comparable sales grew 8.7%.
Adjusted EPS of $2.41 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the consensus</a> estimate of $2.26.
Gross margin for the quarter contracted by 40 basis points to 26.2%, reflecting higher digital fulfillment and supply chain costs and higher promotional and clearance markdown rates.
Operating&nbsp;income margin rate of 4.7% was 110 basis points lower than last year, and the&nbsp;operating income for the quarter plunged 21.3% to $1.47 billion.
The&nbsp;company held $4.7 billion in cash and equivalents&nbsp;as of February 1.&nbsp;Operating cash flow for twelve months totaled $7.4 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/03/44081963/ford-february-us-sales-slide-8-9-ev-sales-jump-15-details" rel="noreferrer noopener">Ford February US Sales Slide 8.9%, EV Sales Jump 15%: Details</a>
Inventory as of February was $12.74 billion, compared to $11.8 billion last year. The company paid dividends of $513 million in the fourth quarter, compared with $508 million last year.
As of the end of the fourth quarter, TGT had approximately&nbsp;$8.7 billion&nbsp;of remaining capacity under the repurchase program approved by the Board of Directors in&nbsp;August 2021.
&#8220;Our team grew traffic and delivered better-than-expected sales and profitability in our biggest quarter of the year,&#8221;&nbsp;said chair and chief executive officer Brian Cornell.
&#8220;Results were led by strong performance in Beauty, Apparel, Entertainment, Sporting Goods and Toys. As we look ahead, our continued investments in digital capabilities, stores and supply chain—combined with a focus on newness, value, speed and reliability—will further differentiate our one-of-a-kind physical and digital shopping experience.&#8221;
Outlook: Target expects FY25 adjusted EPS of $8.80 – $9.80 versus an estimate of $9.31. It sees comparable sales to be flat. The company sees FY25 sales growth <a href="https://www.benzinga.com/calendars/guidance">to be around 1%.</a>
Due to continued consumer uncertainty, a slight drop in February net sales, tariff instability, and the anticipated timing of certain expenses throughout the fiscal year, the company expects to face significant year-over-year profit challenges in the first quarter compared to the rest of the year.
&#8220;During February, we saw record performance around Valentines Day. However, our topline performance for the month was soft, as uncharacteristically cold weather across the U.S. affected apparel sales, and declining consumer confidence impacted our discretionary assortment overall,&#8221; said&nbsp;Jim Lee, chief financial officer.
Price Action: TGT shares traded lower by 1.88% at $118.49 in premarket at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44074819/servicenow-unveils-ai-agents-for-telecoms-in-collaboration-with-nvidia" target="_blank" rel="noreferrer noopener">ServiceNow Unveils AI Agents For Telecoms In Collaboration With Nvidia</a></li>
</ul>
Photo via Shutterstock.

Earnings

Equities

Large Cap

Guidance

General

Target CEO Cautions Tariffs Will Pressure FY25 Profit, Consumer Uncertainty To Hit Feb Sales

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) with a Buy and maintains $16 price target.

Reiteration

CALC

HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target

Biotech

HOTH

Hoth Therapeutics Announces Preclinical Findings On Potential Of Glial Cell Line-Derived Neurotrophic Factor; Says Findings Include Protection Against High-Fat Diet-Induced Obesity, Enhanced Fat Burning and Energy Expenditure, Adipogenesis, Improved Insulin Sensitivity and Glucose Regulation And Reduced Fatty Liver Disease

Mizuho analyst Gregg Moskowitz maintains GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) with a Outperform and lowers the price target from $80 to $72.

GTLB

Mizuho Maintains Outperform on GitLab, Lowers Price Target to $72

Telsey Advisory Group analyst Cristina Fernandez maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Outperform and maintains $67 price target.

ONON

Telsey Advisory Group Maintains Outperform on On Holding, Maintains $67 Price Target

Barclays analyst Ramsey El-Assal downgrades AvidXchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) from Overweight to Equal-Weight and lowers the price target from $13 to $8.

Downgrades

AVDX

Barclays Downgrades AvidXchange Holdings to Equal-Weight, Lowers Price Target to $8

On Tuesday, BioHarvest Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHST#NASDAQ">BHST</a>) published ‘in vitro' test results for its new olive cell compound, which can reduce fat accumulation in human liver cells.
BioHarvest demonstrated that its novel olive cell compound mitigated fat accumulation in human liver cells, both in a liver steatosis model and in experimental liver fibrosis models.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/12/42431837/exclusive-bioharvest-collaborate-with-tate-lyle-to-develop-proprietary-plant-based-molecules" rel="noreferrer noopener">EXCLUSIVE: BioHarvest Collaborates With Tate &amp; Lyle To Develop Proprietary Plant-Based Molecules</a>
The company attributes the reduction of fat accumulation in liver cells to the high levels of Verbascoside (a plant-derived polyphenol with known anti-inflammatory properties that has been researched for various effects on the liver) in BioHarvest's Olive cell compound.
Based on these results and additional studies to be conducted in 2025, the company expects to begin selling the Olive Cell product in 2026 as a nutraceutical product while continuing to explore the potential of partnering with a pharmaceutical company to provide the olive cell composition via a different regulatory path as part of its contract development and production organization (CDMO) model.
The Olive product will join VINIA as part of the company's portfolio. VINIA, a grape cell product that is high in Piceid Resveratrol, has been clinically shown to significantly dilate arteries, resulting in increased blood flow.
The company recently announced that VINIA had surpassed $50 million in sales, with over 50,000 active subscribers.
BioHarvest plans to support future growth by expanding its production capacity by 4x and building a new 100-ton-per-year production facility, which is expected to be <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/43780365/bioharvest-announces-sales-of-flagship-product-vinia-now-exceed-50-million-usd" rel="noreferrer noopener">operational in late 2026</a>.
Price Action: BHST stock closed at $5.03 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/03/44103926/grocery-giant-albertsons-names-susan-morris-as-new-ceo" target="_blank" rel="noreferrer noopener">Grocery Giant Albertsons Names Susan Morris As New CEO</a></li>
</ul>

Health Care

Market-Moving Exclusives

Exclusives

BHST

EXCLUSIVE: Botanical Synthesis Tech-Focused BioHarvest's First Synthetic Olive Cells Shows Reduced Fat Accumulation in Liver Cells

<a href="https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions" title="https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions">https://www.jnj.com/media-center/press-releases/shockwave-medical-launches-novel-forward-intravascular-lithotripsy-platform-in-u-s-to-transform-treatment-of-difficult-to-cross-calcified-lesions</a>

Johnson & Johnson MedTech Says 'Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform In U.S. To Transform Treatment Of Difficult-To-Cross Calcified Lesions'

MARA

MARA Holdings February Bitcoin Product 706 Down From 750 MoM

EXCLUSIVE: BioHarvest Tells Benzinga 'In Vitro Testing of First Lab-Grown Plant-Based Molecules Proves Reduced Fat Accumulation in Liver Cells'

EXCLUSIVE: BioHarvest Tells Benzinga Co. Shows First Synthetic Olive Cells A Capable New Weapon In Fight Against Liver Disease

Press Releases

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024

Alvotech Reports Financial Results for the First Nine Months of 2024

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

Legal

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Comments

Alvotech

Alvotech (ALVO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL